Several mutations and genomic aberrations, although rare, seem to be potentially targetable, such as ALK rearrangements, NTRK fusions, TSC2 mutations or RET rearrangements [93,94], which along with a growing interest in the study of the immune tumor microenvironment, are leading several clinical studies that may have a significant impact in the management of this aggressive subtype of thyroid cancer (Figure 2). The gene discussed is RET; the disease is thyroid gland carcinoma.